ALLO — Allogene Therapeutics, Inc.

Summary of Allogene Therapeutics, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of December 31, 2025, Allogene had $258.3 million in cash, cash equivalents, and investments, with an extended cash runway into 2028.
• Recent Funding: Received $23.7 million from a favorable arbitration outcome and raised an additional $20.7 million through an ATM equity facility.
• Expenses:
  • Q4 R&D expenses: $28.6 million (including $2.5 million in non-cash stock-based compensation).
  • Full-year R&D expenses: $150.2 million (including $12.9 million in non-cash stock-based compensation).
  • Q4 G&A expenses: $13.8 million (including $5.6 million in non-cash stock-based compensation).
  • Full-year G&A expenses: $56.8 million (including $24.7 million in non-cash stock-based compensation).
• Net Loss: Q4 net loss was $38.8 million ($0.17 per share); full-year net loss was $190.9 million ($0.87 per share).

2. Strategic Updates and Business Highlights

• Clinical Focus: Allogene is prioritizing two key programs:
  • SemiCell and ALPHA-3: Aiming to redefine treatment for large B-cell lymphoma by intervening earlier and expanding access to community cancer centers.
  • ALLO-329: A dual CD19/CD70 CAR T therapy targeting autoimmune diseases, with proof-of-concept data expected in June 2026.
• Execution Strategy: Emphasis on disciplined execution and prioritization of high-impact programs to demonstrate the scalability and accessibility of allogeneic CAR T therapies.

3. Forward Guidance and Outlook

• 2026 Operating Cash Expense: Expected to be approximately $150 million, with GAAP operating expenses around $210 million, including estimated non-cash stock-based compensation of $35 million.
• Upcoming Data Releases: Key clinical milestones include interim results from the ALPHA-3 trial in April 2026 and proof-of-concept data for ALLO-329 in June 2026.

4. Bad News, Challenges, or Points of Concern

• Competitive Landscape: The emergence of CD3 bispecifics moving into the frontline treatment may impact the SemiCell market opportunity, potentially reducing the number of patients eligible for treatment.
• Clinical Risks: There are inherent uncertainties regarding the outcomes of ongoing trials, particularly concerning MRD clearance rates and their correlation to clinical benefits.
• Execution Risks: The need for disciplined prioritization may limit the advancement of other promising programs, which could affect long-term growth potential.

5. Notable Q&A Insights

• Safety Parameters: The company plans to provide high-level safety information during the upcoming data update, focusing on serious adverse events and outpatient delivery feasibility.
• MRD Conversion Expectations: The interim analysis will focus on MRD clearance rates, with a target of a 25% to 30% improvement over baseline expected in the ALPHA-3 trial.
• Community Adoption: There is confidence in the community's ability to adopt SemiCell as a treatment option, with ongoing integration into routine practice.
• Autoimmune Program Profile: ALLO-329 is designed to work with low or no lymphodepletion, which could differentiate it from other therapies in the autoimmune space.

This summary encapsulates the key points from the earnings call, providing a balanced view of Allogene Therapeutics' financial health, strategic direction, and potential challenges ahead.